KRAS G12C NSCLC Models Are Sensitive to Direct Targeting of KRAS in Combination with PI3K Inhibition

KRAS-mutant lung cancers have been recalcitrant to treatments including those targeting the MAPK pathway. Covalent inhibitors of KRAS p.G12C allele allow for direct and specific inhibition of mutant KRAS in cancer cells. However, as for other targeted therapies, the therapeutic potential of these in...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical cancer research 2019-01, Vol.25 (2), p.796-807
Hauptverfasser:	Misale, Sandra, Fatherree, Jackson P, Cortez, Eliane, Li, Chendi, Bilton, Samantha, Timonina, Daria, Myers, David T, Lee, Dana, Gomez-Caraballo, Maria, Greenberg, Max, Nangia, Varuna, Greninger, Patricia, Egan, Regina K, McClanaghan, Joseph, Stein, Giovanna T, Murchie, Ellen, Zarrinkar, Patrick P, Janes, Matthew R, Li, Lian-Sheng, Liu, Yi, Hata, Aaron N, Benes, Cyril H
Format:	Artikel
Sprache:	eng
Schlagworte:	Alleles Animals Cell Line, Tumor Cell Proliferation - drug effects Drug Resistance, Neoplasm - genetics Drug Screening Assays, Antitumor Gene Silencing Humans Mice Mutation Phosphatidylinositol 3-Kinases - metabolism Phosphoinositide-3 Kinase Inhibitors - pharmacology Protein Kinase Inhibitors - pharmacology Proto-Oncogene Proteins p21(ras) - antagonists & inhibitors Proto-Oncogene Proteins p21(ras) - genetics Proto-Oncogene Proteins p21(ras) - metabolism Signal Transduction - drug effects
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!